1Fearon ER,Vogelstein B.A genetic model for colorectal tumorigenesis.Cell,1990,61:759-767.
2Jass JR,Biden KG,Cummings MC,et al.Characterisation of a subtype of colorectal cancer combining features of the suppressor and mild mutator pathways.J Clin Pathol,1999,52:455-460.
3Cunningham JM,Christensen ER,Tester DJ,et al.Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability.Cancer Res,1998,58:3455-3460.
4Habano W,Sugai T,Yoshida T,et al.Mitochondrial gene mutation,but not larges-scale deletion,is a feature of colorectal carcinomas with mitochondrial microsatellite instability.Int J Cancer,1999,83:625-629.
5Shannon B,Kay P,House A,et al.Hypermethylation of the MYF-3 gene in colorectal cancers:associations with pathological features and with microsatellite instability.Int J Cancer,1999,84:109-113.
6Maekawa M,Sugano K,Ushiama M,et al.Heterogeneity of DNA methylation status analyzed by bisulfite-PCR-SSCP and correlation with clinico-pathological characteristics in colorectal cancer.Clin Chem Lab Med,2001,39:121-128.
7Shannon BA,Iacopetta BJ.Methylation of the hMLH1,p16,and MDR1 genes in colorectal carcinoma:associations with clinicopathological features.Cancer Lett,2001,167:91-97.
8Wheeler JM,Kim HC,Efstathiou JA,et al.Hypermethylation of the promoter region of the E-cadherin gene (CDH1) in sporadic and ulcerative colitis associated colorectal cancer.Gut,2001,48:367-371.
9Hemminki K,Li X.Familial colorectal adenocarcinoma and hereditary nonpolyposis colorectal cancer:a nationwide epidemiological study from Sweden.Br J Cancer,2001,84:969-974.
10Vasen HF,Watson P,Mecklin JP,et al.New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC,Lynch syndrome) proposed by the International Collaborative group on HNPCC.Gastroenterology,1999,116:1453-1456.
7Badawi AF, Badr MZ. Chemoprevention of breast cancer by targeting cyclooxygenase-2 and peroxisome proliferator-activated receptorgamma(Review) [J]. Int J Oncol,2002,20(6) :1109 -1122.
8Morosetti R, Servidei T, Mirabella M, et al. The PPARgamma ligands PGJ2 and rosiglitazone show a differential ability to inhibit proliferation and to induce apoptosis and differentiation of human glioblastoma cell lines [ J ]. Int J Oncol,200d ,25 ( 2 ) :493 - 502.
9Bird RP. Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen : preliminary findings [J]. Cancer Lett,1987,37(2) :147 - 151.
10Teague TK, Hildeman D, Kedl RM, et al. Activation changes the spectrum but not the diversity of genes expressde by T cells [ J]. Pruc Natl Acad Sci USA, 1999,96 ( 22 ) : 12691 - 12696.
